LGND - Ligand Pharmaceuticals Incorporated
NASDAQ
->
Healthcare
->
Biotechnology
EmeryVille,
United States
Type: Equity
LGND price evolution
LGND
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $18.14 | $50.09 | $22.95 | |
| Short term investments | $228.93 | $260.5 | ||
| Net receivables | $42.13 | $37.48 | $28.43 | $32.92 |
| Inventory | $16.74 | $18.67 | $21.34 | $23.97 |
| Total current assets | $309.39 | $312.26 | $368.91 | $237.43 |
| Long term investments | $13.18 | $46.97 | $48.32 | |
| Property, plant & equipment | $25.19 | $25.46 | $24.38 | $25.06 |
| Goodwill & intangible assets | $388.41 | $396.67 | $470.27 | |
| Total noncurrent assets | $554.15 | $544.96 | $549.79 | |
| Total investments | $242.11 | $307.47 | $147.35 | |
| Total assets | $954.87 | $866.4 | $913.87 | $787.22 |
| Current liabilities | ||||
| Accounts payable | $4.69 | $1.79 | $1.89 | $2.43 |
| Deferred revenue | $3.89 | $4.29 | $2.67 | |
| Short long term debt | $1.17 | $1 | $0.41 | |
| Total current liabilities | $24.77 | $18.57 | $17.82 | $16.78 |
| Long term debt | $6.42 | $5.19 | $5.75 | |
| Total noncurrent liabilities | $72.64 | $89.53 | $69.52 | |
| Total debt | $7.58 | $6.19 | $6.17 | |
| Total liabilities | $113.69 | $91.21 | $107.35 | $86.3 |
| Shareholders' equity | ||||
| Retained earnings | $530.07 | $537.24 | $589.15 | $503.02 |
| Other shareholder equity | $1.75 | -$0.94 | -$0.91 | -$0.82 |
| Total shareholder equity | $775.2 | $806.52 | $700.91 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $22.95 | $45.01 | $19.52 | $47.62 |
| Short term investments | $166.86 | $321.59 | $363.57 | |
| Net receivables | $32.92 | $35.04 | $85.45 | $56.85 |
| Inventory | $23.97 | $13.29 | $27.33 | $26.49 |
| Total current assets | $237.43 | $263.6 | $464.75 | $500.56 |
| Long term investments | $48.32 | |||
| Property, plant & equipment | $25.06 | $15.01 | $53.26 | $37.17 |
| Goodwill & intangible assets | $470.27 | $458.31 | $742.36 | $795.97 |
| Total noncurrent assets | $549.79 | $499.07 | $832.84 | $861.73 |
| Total investments | $147.35 | $166.86 | $321.59 | $363.57 |
| Total assets | $787.22 | $762.67 | $1297.59 | $1362.29 |
| Current liabilities | ||||
| Accounts payable | $2.43 | $20.99 | $8.4 | $3.78 |
| Deferred revenue | $2.67 | $0.35 | $11 | $29.43 |
| Short long term debt | $0.41 | $77.41 | $2.1 | $8.48 |
| Total current liabilities | $16.78 | $98.81 | $41.66 | $100.11 |
| Long term debt | $5.75 | $10.34 | $336.21 | $447.94 |
| Total noncurrent liabilities | $69.52 | $66.37 | $434.77 | $552.65 |
| Total debt | $6.17 | $87.75 | $338.31 | $456.41 |
| Total liabilities | $86.3 | $165.18 | $476.43 | $652.76 |
| Shareholders' equity | ||||
| Retained earnings | $503.02 | $450.86 | $449.09 | $391.95 |
| Other shareholder equity | -$0.82 | $597.49 | -$0.92 | -$0.8 |
| Total shareholder equity | $700.91 | $597.49 | $821.16 | $709.52 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $41.53 | $30.98 | $28.1 | |
| Cost of revenue | $2.91 | $2.88 | ||
| Gross Profit | $38.63 | $28.1 | $26.46 | |
| Operating activities | ||||
| Research & development | $5.35 | $5.97 | ||
| Selling, general & administrative | $17.62 | $10.95 | ||
| Total operating expenses | $57.73 | $25.11 | $29.82 | |
| Operating income | -$19.1 | $2.99 | ||
| Income from continuing operations | ||||
| EBIT | -$64.12 | $113.59 | ||
| Income tax expense | -$13.48 | $27.31 | -$1.09 | |
| Interest expense | $1.27 | $0.14 | $17.84 | |
| Net income | ||||
| Net income | -$51.91 | $86.14 | $18.19 | |
| Income (for common shares) | -$51.91 | $86.14 | ||
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $131.31 | $196.25 | $186.42 | |
| Cost of revenue | $52.83 | $30.42 | ||
| Gross Profit | $120.8 | $143.42 | $156 | |
| Operating activities | ||||
| Research & development | $36.08 | $59.39 | ||
| Selling, general & administrative | $70.06 | $64.44 | ||
| Total operating expenses | $110.98 | $140.38 | $130.16 | |
| Operating income | $3.04 | $25.84 | ||
| Income from continuing operations | ||||
| EBIT | $9.67 | $16.88 | ||
| Income tax expense | $9.84 | $41.23 | -$7.55 | |
| Interest expense | $53.67 | $1.8 | $27.42 | |
| Net income | ||||
| Net income | $52.15 | -$33.36 | -$2.98 | |
| Income (for common shares) | -$33.36 | -$2.98 | ||
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | -$51.91 | $86.14 | ||
| Operating activities | ||||
| Depreciation | $9.36 | $9.24 | ||
| Business acquisitions & disposals | -$77.5 | -$1 | ||
| Stock-based compensation | $11.06 | $7.33 | ||
| Total cash flows from operations | $13.31 | $18.73 | ||
| Investing activities | ||||
| Capital expenditures | -$0.41 | -$0.1 | ||
| Investments | $23.15 | -$2.67 | ||
| Total cash flows from investing | -$105.04 | -$54.76 | -$3.77 | -$11.68 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $9.55 | $15.3 | ||
| Net borrowings | -$0.06 | -$0.05 | ||
| Total cash flows from financing | $76.75 | $9.49 | $12.18 | -$59.98 |
| Effect of exchange rate | $0.38 | |||
| Change in cash and equivalents | $40.66 | -$31.95 | $27.14 | -$22.1 |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$33.36 | $57.14 | -$2.98 | |
| Operating activities | ||||
| Depreciation | $56.89 | $50.95 | $27.97 | |
| Business acquisitions & disposals | -$385.15 | |||
| Stock-based compensation | $60.28 | $38.78 | $29.25 | |
| Total cash flows from operations | $137.85 | $78.8 | $54.59 | |
| Investing activities | ||||
| Capital expenditures | -$17.83 | -$8.27 | -$3.1 | |
| Investments | $182.41 | $40.01 | $615.67 | |
| Total cash flows from investing | -$11.68 | $163.62 | $30.52 | $231.65 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3.23 | $33.76 | -$74.98 | |
| Net borrowings | -$260.8 | -$146.01 | -$231.76 | |
| Total cash flows from financing | -$59.95 | -$275.99 | -$137.76 | -$310.55 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$22.05 | $25.48 | -$28.44 | -$24.31 |
News
Fundamentals
| Market cap | $2.17B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 18.76M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.12 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 12.49 |
| Quick ratio | 11.81 |